AP NEWS
Press release content from Business Wire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from Business Wire
Press release content from Business Wire. The AP news staff was not involved in its creation.

Global Idiopathic Pulmonary Fibrosis (IPF) Market Spotlight 2019-2027: Roche’s Esbriet and Boehringer Ingelheim’s Ofev are the only approved drugs for IPF - ResearchAndMarkets.com

November 4, 2019 GMT

DUBLIN--(BUSINESS WIRE)--Nov 4, 2019--

The “Market Spotlight: Idiopathic Pulmonary Fibrosis (IPF)” report has been added to ResearchAndMarkets.com’s offering.

This Market Spotlight report covers the Idiopathic Pulmonary Fibrosis market, comprising key marketed and pipeline drugs, clinical trials, recent events and analyst opinion, upcoming and regulatory events, probability of success, patent information, 10-year disease incidence and prevalence forecasts, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.

Key Takeaways:

Key Topics Covered:

OVERVIEW

KEY TAKEAWAYS

DISEASE BACKGROUND

TREATMENT

EPIDEMIOLOGY

MARKETED DRUGS

PIPELINE DRUGS

RECENT EVENTS AND ANALYST OPINION

KEY UPCOMING EVENTS

KEY REGULATORY EVENTS

PROBABILITY OF SUCCESS

LICENSING AND ASSET ACQUISITION DEALS

PARENT PATENTS

REVENUE OPPORTUNITY

CLINICAL TRIAL LANDSCAPE

BIBLIOGRAPHY

APPENDIX

Companies Mentioned

For more information about this report visit https://www.researchandmarkets.com/r/3wc14t

View source version on businesswire.com:https://www.businesswire.com/news/home/20191104005337/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

KEYWORD:

INDUSTRY KEYWORD: HEALTH GENERAL HEALTH

SOURCE: Research and Markets

Copyright Business Wire 2019.

PUB: 11/04/2019 05:12 AM/DISC: 11/04/2019 05:12 AM

http://www.businesswire.com/news/home/20191104005337/en